Detalles de la búsqueda
1.
Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.
Biol Blood Marrow Transplant;
20(5): 705-16, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24525279
2.
Dietary risk factors for esophageal cancer based on World Health Organization regions.
Nutrition;
95: 111552, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34999383
3.
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
J Clin Invest;
125(7): 2677-89, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26053664
4.
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Clin Cancer Res;
17(13): 4558-67, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21558406
5.
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
Clin Cancer Res;
15(18): 5937-44, 2009 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19723649
6.
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
J Clin Oncol;
25(24): 3680-7, 2007 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17704416
7.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol;
24(19): 3089-94, 2006 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16809734
8.
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Prostate;
60(3): 197-204, 2004 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15176049
Resultados
1 -
8
de 8
1
Próxima >
>>